Expanded Access Policy

Abata Therapeutics is committed to transforming patient lives with Treg therapies for severe autoimmune and inflammatory diseases. We are working hard to evaluate the potential benefits and risks of our therapies in clinical trials as safely and efficiently as possible. The information from these studies may ultimately support regulatory approval, which would provide patients with sustained access to these therapies.

“Expanded Access,” also known as “Compassionate Use,” is a pathway that may be used to provide access to an investigational medical product for a severe condition outside of a clinical trial when no other suitable treatment options are available, and participation in a clinical trial is not possible. At this time, Abata Therapeutics does not have an Expanded Access Program (EAP) that enables patients to access our investigational therapies outside of clinical trials.

Patients interested in our investigational medicines or clinical trials should discuss them with their physician. Healthcare providers and patients can find information about our development pipeline and clinical trials on our website (https://abatatx.com/our-programs/) or by visiting www.clinicaltrials.gov and searching for Abata Therapeutics. If you have questions, please contact us at abatatxclinicaltrials@abatatx.com.

Abata Therapeutics reserves the right to revise this expanded access policy at any time.